Industry News - Ractigen Therapeutics

Company News Homepage News Industry News News Highlight RAG-17 RAG-17 Presentation Uncategorized

Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China, August 6, 2026 – Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA…

Ractigen08/06/2026

Company News Homepage News Industry News News Highlight Uncategorized

Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy

RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way…

Ractigen07/31/2026

Company News Homepage News Industry News News Highlight Uncategorized

Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms

Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and…

Ractigen07/29/2026

Industry News

Delivery of p21 saRNA into rectum shows antitumor efficacy in a preclinical study

A recent study published in Biomaterials's ahead of print issue of June reported in vivo…

ractigen07/15/2017